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Abstract
Background: In order to change antibiotic prescribing behaviour, we need to understand the prescribing process.
The aim of this study was to identify targets for antibiotic stewardship interventions in hospitals through analysis of
the antibiotic prescribing process from admission to discharge across five groups of infectious diseases.
Methods: We conducted a multi-centre, observational cohort study, including patients with lower respiratory tract
infections, exacerbation of chronic obstructive pulmonary disease, skin- and soft tissue infections, urinary tract
infections or sepsis, admitted to wards of infectious diseases, pulmonary medicine and gastroenterology at three
teaching hospitals in Western Norway. Data was collected over a 5-month period and included antibiotics
prescribed and administered during admission, antibiotics prescribed at discharge, length of antibiotic therapy,
indication for treatment and discharge diagnoses, estimated glomerular filtration rate (eGFR) on admission,
antibiotic allergies, place of initiation of therapy, admittance from an institution, patient demographics and
outcome data. Primary outcome measure was antibiotic use throughout the hospital stay, analysed by WHO
AWaRe-categories and adherence to guideline. Secondary outcome measures were a) antibiotic prescribing
patterns by groups of diagnoses, which were analysed using descriptive statistics and b) non-adherence to the
national antibiotic guidelines, analysed using multivariate logistic regression.
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Results: Through analysis of 1235 patient admissions, we identified five key targets for antibiotic stewardship
interventions in our population of hospital inpatients; 1) adherence to guideline on initiation of treatment, as this
increases the use of WHO Access-group antibiotics, 2) antibiotic prescribing in the emergency room (ER), as 83.6%
of antibiotic therapy was initiated there, 3) understanding prescribing for patients admitted from other institutions,
as this was significantly associated with non-adherence to guideline (OR = 1.44 95% CI 1.04, 2.00), 4) understanding
cultural and contextual drives of antibiotic prescribing, as non-adherent prescribing differed significantly between
the sites of initiation of therapy (between hospitals and ER versus ward) and 5) length of therapy, as days of
antibiotic therapy was similar across a wide range of diagnoses and with prolonged therapy after discharge.
Conclusions: Analysing the process of antibiotic prescribing in hospitals with patient-level data identified important
targets for antibiotic stewardship interventions in hospitals.
Keywords: Antimicrobial, Stewardship, Antibiotic, Prescribing, Process, AWaRe, Guideline, Hospital, Target,
Intervention
Background
Suboptimal use of antibiotics is a key driver of antibiotic
resistance [1]. In order to improve the antibiotic pre-
scribing process, we need to understand it. Historically,
antibiotic sales statistics have been easy to collect, and
are therefore widely used as a proxy indicator to monitor
antibiotic prescribing [2–5]. Although analyses of anti-
biotic sales data are useful at an aggregated level, they
do not specify patient level use or outcomes. Whilst pro-
viding a baseline, such data cannot be used to assess the
appropriateness of antibiotic prescribing, limiting oppor-
tunities for optimising antibiotic stewardship interven-
tions. Accurate, patient level assessment of antibiotic
prescribing is an essential step in optimising antibiotic
use. Audit and prevalence studies with manual data col-
lection are time-consuming, but often necessary to re-
trieve this information. Many hospitals still lack
electronic medical records that allow automated extrac-
tion of antibiotic prescription data with accompanying
indications for treatment [6–8]. The introduction of
WHO Access, Watch and Reserve (AWaRe) categories
have provided a framework for analysing antibiotic con-
sumption, focusing on limiting unnecessary use of watch
and reserve antibiotics [9, 10]. We present the findings
of an observational multicentre cohort study aiming to
identify targets for antibiotic stewardship interventions
by analysing the antibiotic prescribing process from ad-
mission to discharge for individual patients.
Methods
Study design and setting
This was an observational, multicentre cohort study
across the wards of infectious diseases, pulmonary medi-
cine and gastroenterology at three teaching hospitals in
Western Norway [11]. The largest hospitals (denoted A
and B hereafter) are emergency care, university hospitals
with 1100 and 600 beds, respectively, covering most spe-
cialities, except transplant surgery. Hospital C is an
emergency care, teaching hospital with 160 beds, which
is in close collaboration with Hospital A.
Data collection
The cohort included patients recruited to an antibiotic
stewardship intervention study and consisted of adult
patients discharged from study wards between the 10th
of February and the 11th of July 2014 with a hospital
stay ≥24 h and ≤ 21 days, receiving antibiotics during ad-
mission for an indication within guideline recommenda-
tions [11, 12]. If a patient was readmitted during the
study period, only the first stay was included. Patients
with the following indications were included in the ana-
lysis: 1) lower respiratory tract infections (LRTI) 2) ex-
acerbation of Chronic Obstructive Pulmonary Disease
(COPD ex) 3) urinary tract infections (UTI) 4) skin- and
soft tissue infections (SSTI) and 5) sepsis. Patients were
excluded if: a) they were admitted to intervention wards
in the post-intervention period; and b) comorbidity and
patient outcome data were missing.
Data were collected manually from electronic medical
records, including admission notes from the emergency
room, medical charts, physicians’ clinical notes, dis-
charge letters and laboratory test results. Data included
patient demographics, indication for antibiotic treat-
ment, antibiotic use throughout the hospital stay, dis-
charge diagnoses, estimated glomerular filtration rate
(eGFR) on admission, length of stay, 30-day readmission,
in-hospital and 30-day mortality, comorbidity and ad-
mittance from institution. Coded data on discharge diag-
noses were retrieved from the hospital administrative
system.
Outcomes
The primary outcome measure was antibiotic regimens
used throughout the hospital stay, grouped by AWaRe-
categories and guidelines adherence on initiation of
treatment and analysed at initiation of treatment, after
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first modification of regimen, and at discharge. Second-
ary outcome measures were antibiotic prescribing pat-
terns by groups of diagnoses and non-adherence to the
national antibiotic guidelines, analysed as association
with study variables.
Patient characteristics and diagnoses
To assess comorbidity, the Charlson Comorbidity Index
(CCI) was calculated based on ICD-10 diagnoses at dis-
charge [13, 14]. CCI was categorised as CCI equal to 0,
1, 2, 3, 4 or > 4, with zero being no registered comorbid-
ity and > 4 substantial comorbidity.
The initial working diagnosis, documented in the elec-
tronic medical record for prescribed antibiotics, was
used as the principal indication. Patients and treatment
regimens were grouped by indications according to Sup-
plement 1, Table 1. For patients having several diagno-
ses, all diagnoses were documented and a variable
indicating multiple working diagnosis was created. Co-
author BS (Infectious diseases (ID)-physician) assessed
patients with multiple working diagnoses and assigned a
primary indication for treatment based on the expect-
ation that the treating physicians were likely to choose
antibiotic treatment covering the most severe working
diagnosis. Accuracy of diagnoses was defined as the per-
centage of patients for whom the initial indication for
antibiotic treatment matched the discharge diagnosis
(group level), defined as the infectious disease diagnosis
coded or written in free text in the discharge letter.
Antibiotic prescribing
Antibiotic regimens could include single or multiple an-
tibiotics. Initially prescribed antibiotic regimens were
assessed for adherence according to the Norwegian na-
tional antibiotic guidelines, as all hospitals included the
national guidelines in their local antibiotic policy. Only
first-choice empirical regimen for a given indication was
regarded adherent. Assessment of adherence was per-
formed using automated syntax in SPSS for Windows
(IBM SPSS Statistics, version 24, USA). Indication for
treatment was combined with prescribed active sub-
stance(s) to generate the adherence variable and adher-
ence was thereafter adjusted manually for patients with
kidney failure or antibiotic allergies.
Anti-infectives for systemic use (ATC-group J01),
metronidazole tablets (ATC code P01AB01) and vanco-
mycin tablets (A07AA09) were defined as antibiotics in
this study. The prescribed antibiotic regimens were
assigned to WHO AWaRe categories [9, 15]. For over-
view of AWaRe categories and included antibiotics, see
Supplement 1, Table 2. Antibiotics belonging only to the
“key access” category were included in the “access” cat-
egory, while antibiotics belonging to “access-watch” and
“watch” were included in the watch category. Since the
use of antibiotics in the “reserve” category was minimal,
the groups of “watch” and “reserve” were combined for
analysis. Several antibiotics frequently used in Norway
are not included in WHO AWaRe categories. To be able
to include these patients in analysis, a modified version
of AWaRe categories was prepared (Supplement 1, Table
2). Of the antibiotics not included in the original AWaRe
categories, mecillinam, pivmecillinam, metenamin and
tobramycin were added to the “access” category and
cefuroxime was added to the “watch” category. If an
antibiotic regimen contained both access and watch/re-
serve-group antibiotics, the regimen was classified as
watch/reserve.
Modification of antibiotic therapy
Modifications that prescribing physicians made to the
first antibiotic regimen were defined in four categories:
escalation, de-escalation, change within same level or
unchanged. Day 1 was the day antibiotic therapy was ini-
tiated. Patients with regimens in the unchanged category
were not included in analysis of time to change. Defini-
tions of modifications are given in Table 1. Assessment
of antimicrobial spectrum and categorisation of change
were performed and checked by ID-physicians (authors
BS and IS, respectively). Examples are given in Supple-
ment 1, Table 3.
Duration of antibiotic therapy
Duration of antibiotic therapy was measured in days
from the first to the last day of therapy and reported as:
1) mean total days of treatment, including prescribed
treatment after discharge, 2) mean days of in-hospital
antibiotic therapy and 3) mean days of therapy after dis-
charge. When antibiotic treatment continued after dis-
charge, the day of discharge was counted as in-hospital
therapy. Information about antibiotic therapy after dis-
charge was retrieved from the discharge letter and also
reported as percentage of patients where post-discharge
antibiotics were described.
Data analysis
Descriptive statistics were applied to describe the pre-
scription patterns. To examine which factors were asso-
ciated with non-adherence, we used univariate and
multivariate logistic regression. A targeted selection of
factors were evaluated for the multivariate logistic re-
gression model: place of antibiotic therapy initiation, in-
dication for treatment, hospital site, admission from
institution, accuracy between indication for treatment
and discharge infection diagnosis, sex, age group, comor-
bidity measured by CCI, multiple working diagnoses,
antibiotic allergies and eGFR. Variables that in univariate
analysis had a p-value of less than 0.2 were included in
the final model. Only the first four variables were
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associated with non-adherence in univariate analysis and
included in the final multivariate model. P-values below
0.05 were considered statistically significant for all ana-
lysis. Stata SE version 15 (Stata Statistical Software, Col-
lege Station, TX, USA) was used for all statistical
analysis, while SPSS for Windows (IBM SPSS Statistics,
version 24, USA) was used for assessment of adherence.
Results
During the study period, 1544 patients with available co-
morbidity and outcome data met the inclusion criteria.
Of these patients, 309 were admitted in the post-
intervention period at intervention wards and was there-
fore excluded, leaving 1235 unique patients included in
analysis for this study.
Diagnoses and patient characteristics
The characteristics of the patients are given in Table 2.
The most frequent diagnosis was LRTI (33.4%), followed
by COPD exacerbations (22.7%), sepsis (20.1%), SSTI
(12.2%) and UTI (11.7%) (not shown in tables). In the
group of patients with SSTI, 6.0% of patients were ad-
mitted from an institution, compared to 20.7% for pa-
tients with UTI. When investigating accuracy between
the groups of indications for empirical antibiotic treat-
ment and discharge infection diagnoses, there was sub-
stantial variation with a range from 41.5% accuracy for
patients initially diagnosed with sepsis, to 95.3% for pa-
tients diagnosed with SSTI.
Empirical antibiotic prescribing
Prescribed antibiotic regimens were adherent to guide-
lines for 63% of patients (Table 3). Antibiotics belonging
to the WHO AWaRe “Access” category were prescribed
as initial regimen for 74% of patients in total, while the
remaining 26.0% of antibiotic regimens were from the
“Watch/Reserve” category. Where initial antibiotic
regimens were adherent to guidelines, 89% of regimens
were in the WHO AWaRe access category (Fig. 1). Sec-
ond regimens included more antibiotics from the watch/
reserve categories and 71% of regimens were now in the
access category. At discharge, 85% of regimens from the
adherent group were in the access category. Where ini-
tial antibiotic regimens were non-adherent to guidelines,
49% of the regimens were in the access category. This
increased to 61% for the second regimen and then again
to 74% of regimens being the access category at
discharge.
The majority (83.6%) of antibiotic prescriptions were
initiated in the emergency room, ranging from 64.8% of
prescriptions for UTI to 96.8% for sepsis (Table 3). Initi-
ating antibiotic therapy at the ward increased the likeli-
hood for non-adherence to guidelines, compared to
prescribing in the emergency room, with an odds-ratio
(OR) of 1.7, 95% CI (1.24, 2.36) (Table 4). When com-
pared to LRTI, all groups of diagnoses were associated
with a higher likelihood of non-adherence, ranging from
OR = 1.42, 95% CI (1.03, 1.98) for COPD ex to OR =
1.62, 95% CI (1.09, 2.41) for UTI (all p < 0.05). Being ad-
mitted to hospital B was associated with reduced OR of
non-adherence compared to hospital A, with an OR =
0.63, 95% CI (0.46, 0.86), p = 0.004. Patients admitted
from an institution had increased risk of receiving non-
adherent antibiotic treatment, OR = 1.44, 95% CI (1.04,
2.00), p = 0.029. Other factors tested were not associated
with prescriptions being non-adherent to guidelines.
Modification of antibiotic therapy
The initial antibiotic regimen was modified during ad-
mission for 61.4% of the patients, and 20.6% of initial
regimens was continued until discharge and then chan-
ged (Table 3). For the remaining patients, the initial
antibiotic regimen was either stopped (9.7%) or contin-
ued after discharge (8.3%). This pattern varied between
Table 1 Modifications of antibiotic regimens
Process measures Definition
Modification of therapy
Escalation Change from oral to intravenous (i.v.) antibiotic treatment within the same antibacterial spectrum,
change to more broad-spectrum treatment, adding an antibiotic to a combination.
De-escalation Change from i.v. to oral antibiotic treatment within the same antibacterial spectrum or change to
more narrow-spectrum treatment.
Change same level Change to a regimen within the same antibacterial spectrum and form of administration (i.v./oral).
Unchanged Regimens where first change of therapy was discontinuation of antibiotics, either during admission
or after discharge.
Time to first modification of AB regimen Time to first escalation/de-escalation/change within same antibacterial spectrum and dosage form
(change of active substance(s), i.v. to oral switch, stopping or adding an antibiotic).
Number of treatment regimens The number of treatment regimens from initiation of treatment until antibiotics prescribed at
discharge
Day of oral antibiotics The first day that one or more oral antibiotics were given.
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diagnoses. For patients with sepsis, 82.7% of initial anti-
biotic regimens were changed during admission, in con-
trast to 54.7 and 50.3% of regimens for SSTI and UTI
patients, respectively.
De-escalation was the most frequent first modification
of antibiotic regimens and in total, 56.4% of first modifica-
tions were de-escalations, across all diagnoses (Table 3).
For patients whose therapy was modified, the mean day of
change was 3.6 days with 95% CI (3.5, 3.8). The time from
start of antibiotic therapy to first change varied from pa-
tients with sepsis where day 3.0 with 95% CI (2.7, 3.3) was
the mean day of change to patients with LRTI where
change occurred on day 4.0 with 95% CI (3.7, 4.2).
In total, 84.5% of patients received oral antibiotics dur-
ing the course of treatment (Table 3). Time to oral treat-
ment differed substantially between diagnoses, from 2.7
days, 95% CI (2.3, 3.1) for UTI’s to 5.1 days, 95% CI (4.6,
5.5) for sepsis.
Duration of antibiotic therapy
The mean duration (in-house and post-discharge) of
antibiotic therapy was 10.6 days, 95% CI (10.3, 10.9)
(Table 3). Mean days of in-house and post-discharge
therapy was similar across all diagnosis. Patients diag-
nosed with sepsis had the highest mean number of in-
house antibiotic days at 6.6 days, 95% CI (6.1, 7.1), while
patients with SSTI had the highest mean days of therapy
after discharge and total days of antibiotics with 7.1, 95%
CI (6.4, 7.7) and 12.5 days 95% CI (11.6, 13.4), respect-
ively. After discharge, 77.4% of patients continued with
antibiotic therapy.
Table 2 Patient characteristics
LRTI (n = 412)
n (%)
COPD ex (n = 280)
n (%)
Sepsis (n = 248)
n (%)
SSTI (n = 150)
n (%)
UTI (n = 145)
n (%)
Total (N = 1235)
n (%)
Sex
Male 196 (47.6) 149 (53.2) 148 (59.7) 101 (67.3) 62 (42.8) 656 (53.1)
Female 216 (52.4) 131 (46.8) 100 (40.3) 49 (32.7) 83 (57.2) 579 (46.9)
Age
< = 45 43 (10.4) 2 (0.7) 51 (20.6) 52 (34.7) 16 (11.0) 164 (13.3)
46–65 88 (23.4) 70 (25.0) 50 (20.2) 48 (32.0) 21 (14.5) 277 (22.4)
66–85 192 (46.6) 179 (63.9) 106 (42.7) 37 (24.7) 71 (49.0) 585 (47.4)
> 85 89 (21.6) 29 (10.4) 41 (16.4) 13 (8.7) 37 (25.5) 209 (16.9)
Charlson Comorbidity Index
CCI = 0 163 (39.6) 8 (2.9) 111 (44.8) 108 (72.0) 72 (49.7) 462 (37.4)
CCI = 1 109 (26.5) 178 (63.6) 73 (29.4) 23 (15.3) 37 (25.5) 420 (34.0)
CCI = 2 58 (14.1) 47 (16.8) 41 (16.5) 9 (6.0) 21 (14.5) 176 (14.3)
CCI = 3 32 (7.8) 24 (8.6) 9 (3.6) 5 (3.3) 9 (6.2) 79 (6.4)
CCI = 4 14 (3.4) 18 (6.4) 6 (2.4) 3 (2.0) 1 (0.7) 42 (3.4)
CCI > 4 36 (8.7) 5 (1.8) 8 (3.2) 2 (1.3) 5 (3.5) 56 (4.5)
Admitted from institution
No 341 (82.8) 255 (91.1) 203 (81.9) 141 (94.0) 115 (79.3) 1055 (85.4)
Yes 71 (17.2) 25 (8.9) 45 (18.1) 9 (6.0) 30 (20.7) 180 (14.6)
AB allergies
Yes 43 (10.5) 38 (13.6) 19 (7.7) 13 (8.7) 9 (6.2) 122 (9.9)
No 367 (89.3) 1 missing 242 (86.4) 229 (92.3) 137 (91.3) 136 (93.8) 1111 (90.0) 1 missing
eGFR on admission
> 50 308 (74.8) 230 (82.1) 187 (75.4) 129 (86.0) 101 (69.7) 955 (77.3)
10–50 103 (25.0) 49 (17.5) 59 (23.8) 21 (14.0) 43 (29.7) 275 (22.3)
< 10 1 (0.24) 0 (0.0) 2 (0.8) 0 (0.0) 1 (0.7) 4 (0.32)
Dialysis 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.08)
30-day mortality 55 (13.4) 19 (6.8) 22 (8.9) 2 (1.3) 6 (4.1) 104 (8.4)
30-day readmission 78 (18.9) 76 (27.1) 39 (15.7) 26 (17.3) 37 (25.5) 256 (20.7)
Mean LOS (95% CI) 7.3 (6.8, 7.7) 6.8 (6.3, 7.2) 7.1 (6.6, 7.6) 6.3 (5.6, 7.0) 7.0 (6.3, 7.7) 7.0 (6.7, 7.2)
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Table 3 Antibiotic (AB) prescribing in hospitals – process measures
LRTI (n = 412)
n (%)
COPD ex (n = 280)
n (%)
Sepsis (n = 248)
n (%)
SSTI (n = 150)
n (%)
UTI (n = 145)
n (%)
Total (N = 1235)
n (%)
AB initiated
Emergency room 320 (77.7) 244 (87.1) 240 (96.8) 135 (90.0) 94 (64.8) 1033 (83.6)
Ward 92 (22.3) 36 (12.9) 8 (3.2) 15 (10.0) 51 (35.2) 202 (16.4)
Adherence to guideline
Yes 280 (68.0) 177 (63.2) 151 (60.9) 90 (60.0) 80 (55.2) 778 (63.0)
No 132 (32.0) 103 (36.8) 97 (39.1) 60 (40.0) 65 (44.8) 457 (37.0)
Accuracy between indication for AB-treatment and discharge infection diagnosesa
Yes 331 (80.3) 255 (91.1) 103 (41.5) 143 (95.3) 122 (84.1) 954 (77.3)
No 81 (19.7) 25 (8.9) 145 (58.5) 7 (4.7) 23 (15.9) 281 (22.8)
Empirical AB regimen was
Changed during admission 232 (56.3) 167 (59.6) 205 (82.7) 82 (54.7) 73 (50.3) 759 (61.4)
Changed at discharge 99 (24.0) 57 (20.4) 22 (8.9) 57 (38.0) 19 (13.1) 254 (20.6)
Continued at discharge 32 (7.8) 29 (10.4) 2 (0.8) 5 (3.3) 34 (23.5) 102 (8.3)
Stopped 49 (11.9) 27 (9.6) 19 (7.7) 6 (4.0) 19 (13.1) 120 (9.7)
Empirical AB regimen was
De-escalated 227 (55.1) 176 (62.9) 142 (57.3) 95 (63.3) 56 (38.6) 696 (56.4)
Escalated 84 (20.4) 45 (16.1) 43 (17.3) 29 (19.3) 24 (16.5) 225 (18.2)
Changed-equal spectrum 19 (4.6) 3 (1.1) 41 (16.5) 15 (10.0) 12 (8.3) 90 (7.3)
Unchangedb 82 (19.9) 56 (20.0) 22 (8.9) 11 (7.3) 53 (36.6) 224 (18.1)
Time to change of first AB regimen (n = 1011)
Mean (95% CI)c 4.0 (3.7, 4.2) 3.9 (3.7, 4.1) 3.0 (2.7, 3.3) 3.4 (3.1, 3.8) 3.5 (3.1, 3.9) 3.6 (3.5, 3.8)
Number of treatment regimens through admission
1 41 (9.9) 33 (11.8) 5 (2.0) 6 (4.0) 34 (23.5) 119 (9.6)
2 245 (59.5) 187 (66.8) 86 (34.7) 77 (51.3) 75 (51.7) 670 (54.3)
3 92 (22.3) 43 (15.4) 122 (49.2) 44 (29.3) 29 (20.0) 330 (26.7)
> 3 34 (8.3) 17 (6.1) 35 (14.1) 23 (15.3) 7 (4.8) 116 (9.4)
Oral AB given
Yes 326 (79.1) 243 (86.8) 204 (82.3) 136 (90.7) 135 (93.1) 1044 (84.5)
No 86 (20.9) 37 (13.2) 44 (17.7) 14 (9.3) 10 (6.9) 191 (15.5)
Mean first day (95% CI) 4.2 (3.9, 4.5) 3.6 (3.3, 3.8) 5.1 (4.6, 5.5) 4.8 (4.3, 5.3) 2.7 (2.3, 3.1) 4.1 (3.9, 4.3)
First change of AB regimen
During admission 232 (56.3) 167 (59.6) 205 (82.7) 82 (54.7) 73 (50.3) 759 (61.5)
At discharge 99 (24.0) 57 (20.4) 22 (8.9) 57 (38.0) 19 (13.1) 254 (20.6)
Continued at discharge 32 (7.8) 29 (10.4) 2 (0.8) 5 (3.3) 34 (23.5) 102 (8.3)
Stopped 49 (11.9) 27 (9.6) 19 (7.7) 6 (4.0) 19 (13.1) 120 (9.7)
Antibiotics prescribed at discharge
Yes 296 (71.8) 214 (76.4) 193 (77.8) 139 (92.7) 114 (78.6) 956 (77.4)
No 116 (28.2) 66 (23.6) 55 (22.2) 11 (7.3) 31 (21.4) 279 (22.6)
Days of AB treatment
Mean (95% CI)d 10.2 (9.7, 10.6) 10.0 (9.6, 10.5) 11.5 (10.8, 12.2) 12.5 (11.6, 13.4) 9.3 (8.6, 10.1) 10.6 (10.3, 10.9)
In-hospital 6.3 (5.9, 6.7) 6.0 (5.7, 6.4) 6.6 (6.1, 7.1) 6.0 (5.3, 6.6) 5.3 (4.8, 5.8) 6.2 (5.9, 6.4)
After dischargee 5.5 (5.2, 5.8) 5.2 (4.9, 5.6) 6.3 (5.8, 6.8) 7.1 (6.4, 7.7) 4.9 (4.5, 5.3) 5.8 (5.6, 6.0)
a Measured as match between initial grouped indication for treatment and grouped discharge diagnosis
b "Unchanged" includes patients where discontinuation of antibiotics was the only change
c Does not include patients who did not change initial antibiotic regimen (stop was only change)
d Does not include 40 patients where lenght of prescription treatment after discharge not stated in the discharge letter
e Does not include 40 patients where length of prescription treatment was not stated in the discharge letter and 5 patients where length of prescriptions
treatment was longer than 30 days
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Discussion
This study has identified key gaps and potential targets
in the antibiotic prescribing process in hospitals for anti-
biotic stewardship interventions (Table 5).
One of the main aims of antibiotic stewardship pro-
grams is to reduce unnecessary use of broad-spectrum
antibiotics. We applied WHO AWaRe categories to de-
scribe the categories of antibiotics prescribed and found
that when initial antibiotic treatment were according to
Norwegian national guidelines, the majority of regimens
(89%) consisted of only access group antibiotics. Non-
adherent empirical regimens however, included several
antibiotics from the watch/reserve category, but these
regimens were often switched to regimens within the ac-
cess categories upon first modification of treatment. At
discharge, a greater number of regimens were from the
access category, both suggestive of clinical microsystems
that tried to adhere to guidelines and antibiotic steward-
ship principles, but also likely related to the restricted
availability of oral broad-spectrum antibiotics in
Norway.
In an American study from 2014, Braykov et al. ranked
antibiotics in categories of narrow-spectrum, broad-
spectum, extended spectrum and restricted antibiotics
[16]. Although there are some differences between the
studies regarding the categories used to classify antibi-
otics, the results show that the prescription pattern is
very different between the hospitals in the two studies.
While 74% of patients in our study initially received an-
tibiotics belonging only to the access group, most pa-
tients (78%) had broad-spectrum and extended spectrum
antibiotics prescribed as empirical therapy in the
Braykov-study. This reflects the nature of the Norwegian
national antibiotic guidelines, which mainly have antibi-
otics from the access group as first-line empirical treat-
ment recommendations.
Initiating empirical antibiotic therapy is a crucial step
in the treatment of infections and an important target
for antibiotic stewardship interventions, as recently out-
lined by Tamma et al. in their paper describing the four
moments of antibiotic decision making [17]. In our
study, antibiotics were mainly prescribed in the emer-
gency departments. The physicians responsible for pre-
scribing are usually interns and residents and in
Norwegian hospitals, junior doctors rely heavily on
guidelines for antibiotic prescribing [18]. From a separ-
ate study by Skodvin et al., including patients from the
same intervention study cohort, we also know that mean
compliance with guidelines recommendations for micro-
biology testing practices was 89% [19]. Most patients
(83.6%) started antibiotic treatment in the emergency
departments and non-adherence to guidelines was
higher when treatment was initiated at the wards, com-
pared to the emergency departments (OR = 1.7, 95% CI
(1.24–2.36), p = 0.001). Other studies report reluctance
from other medical teams to change therapy further
down the line and together this highlights the need to
focus on first-line clinical staff when planning antibiotic
stewardship interventions [20].
Non-adherence to guidelines was also associated with
hospital site and whether patients were admitted from
an institution or not. Patients admitted from nursing
homes or other institutions may have had treatment
prior to hospital admission. A combination of age,
frailty, comorbidity and increased fear of resistant bac-
teria as cause of infection could have caused physicians
Fig. 1 Antibiotic regimens prescribed from admission to discharge, by AWaRe categories and adherence to guideline on initiation of therapy
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Table 4 Factors associated with non-adherence to antibiotic guideline
Adherence (n = 778)
n (%)
Non-adherence







Emergency room 670 (64.9) 363 (35.1) 1 1
Ward 108 (53.5) 94 (46.5) 1.6 (1.18, 2.18) 0.002 1.7 (1.24, 2.36) 0.001
Indication for treatment
LRTI 280 (68.0) 132 (32.0) 1 1
COPD ex 177 (63.2) 103 (36.8) 1.23 (0.90, 1.70) 0.196 1.42 (1.03, 1.98) 0.035
Sepsis 151 (60.9) 97 (39.1) 1.36 (0.98, 1.89) 0.065 1.44 (1.02, 2.02) 0.037
SSTI 90 (60.0) 60 (40.0) 1.41 (0.96, 2.10) 0.079 1.56 (1.05, 2.31) 0.028
UTI 80 (55.2) 65 (44.8) 1.72 (1.17, 2.54) 0.006 1.62 (1.09, 2.41) 0.017
Hospital
Hospital A 376 (60.8) 242 (39.2) 1 1
Hospital B 203 (70.7) 84 (29.3) 0.64 (0.48, 0.87) 0.004 0.63 (0.46, 0.86) 0.004
Hospital C 199 (60.3) 131 (39.7) 1.02 (0.78, 1.34) 0.872 0.95 (0.71, 1.26) 0.712
Admitted from institution
No 678 (64.3) 377 (35.7) 1
Yes 100 (55.6) 80 (44.4) 1.44 (1.04, 1.98) 0.026 1.44 (1.04, 2.00) 0.029
Accuracy between indication for AB-treatment and discharge infection diagnosesb
Yes 604 (63.3) 350 (36.7) 1 1
No 174 (61.9) 107 (38.1) 1.06 (0.81, 1.40) 0.671 0.99 (0.72, 1.35) 0.936
Sex
Male 411 (62.7) 245 (37.3) 1 1
Female 367 (63.4) 212 (36.6) 0.97 (0.77. 1.22) 0.790 0.98 (0.77, 1.24) 0.857
Age
< 45 106 (64.6) 58 (35.4) 1 1
46–65 168 (60.7) 109 (39.3) 1.19 (0.79, 1.77) 0.405 1.26 (0.83, 1.91) 0.277
66–85 367 (62.7) 218 (37.3) 1.09 (0.76, 1.56) 0.656 1.08 (0.73, 1.60) 0.695
> 85 137 (65.6) 72 (34.4) 0.96 (0.63, 1.47) 0.854 0.87 (0.54, 1.37) 0.540
Charlson Comorbidity Index
CCI = 0 304 (65.8) 158 (34.2) 1 1
CCI = 1 265 (63.1) 155 (36.9) 1.13 (0.85, 1.48) 0.402 1.14 (0.83, 1.56) 0.421
CCI = 2 102 (57.9) 74 (42.1) 1.40 (0.98, 1.99) 0.066 1.35 (0.93, 1.97) 0.115
CCI = 3 48 (60.8) 31 (39.2) 1.24 (0.76, 2.10) 0.386 1.20 (0.72, 2.02) 0.482
CCI = 4 26 (61.9) 16 (38.1) 1.18 (0.62, 2.27) 0.611 1.18 (0.60, 2.33) 0.626
CCI > 4 33 (58.9) 23 (41.1) 1.34 (0.76, 2.36) 0.310 1.39 (0.77, 2.51) 0.279
Number of working diagnoses
1 493 (64.6) 270 (35.4) 1 1
2 238 (60.7) 154 (39.3) 1.18 (0.92, 1.52) 0.193 1.12 (0.87, 1.46) 0.381
3 47 (58.8) 33 (41.2) 1.28 (0.80, 2.05) 0.299 1.18 (0.73, 1.92) 0.491
Antibiotic allergiesc
No 708 (63.7) 403 (36.3) 1 1
Yes 69 (56.6) 53 (43.4) 1.35 (0.92, 1.97) 0.120 1.40 (0.95, 2.06) 0.088
eGFR
eGFR > 50 598 (62.6) 357 (37.4) 1 1
eGFR < 50 180 (64.3) 100 (35.7) 0.93 (0.71, 1.23) 0.611 0.88 (0.66, 1.17) 0.378
a All factors are adjusted for where AB was initiated, indication for AB treatment, hospital and admittance from institution
b Measured as match between initial grouped indication for treatment and grouped discharge diagnosis
c1 data missing
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to prescribe more broad-spectrum antibiotics for these
patients. There is however, a need for a more thorough
understanding of prescribing practices in this particular
group of patients. Studies show that organisational cul-
ture influence antibiotic prescribing [20–22]. This could
potentially explain why the odds ratio for non-adherent
prescribing was significantly lower at hospital B than the
two other included hospitals (OR = 0.63 95% CI (0.46,
0.86), p = 0.004). It also signals that a thorough under-
standing of organisational culture with barriers and facil-
itators for prudent antibiotic prescribing is an important
part of planning for antibiotic stewardship interventions.
Empirical antibiotic regimens were usually modified
during admission (61.5%) and oral antibiotics were pre-
scribed for 84.5% of patients. Other studies looking at
the process of antibiotic prescribing in hospitals have fo-
cused on review of empirical therapy in relation to pa-
tient outcome or effect of interventions on prescribing
process measures [23–25]. Braykov et al. found that by
the 5th day of therapy, 21,5% of empirical antibiotics
were narrowed or discontinued, while Aillet et al. found
that antibiotic review was performed in 69% of patients
with bacteraemia [16, 24]. In comparison, although we
did not measure all patients at one specific day, 74,5% of
empirical antibiotics were de-escalated (56,4%) and
stopped (18,1%) as first modification of therapy in our
study. Modifications happened between day 3 and 4
when initiation of therapy was defined as day 1. This is
in agreement with recommendations stating that review
of therapy should take place 48–72 h after initiation of
antibiotic therapy [26–28]. Upon discharge, 77.4% of pa-
tients continued antibiotic treatment and the mean
length of post-discharge therapy was similar to the mean
length of in-house treatment. This could mean either
that most patients were not fully recovered upon dis-
charge or that antibiotics were continued “just in case,”
justifying an earlier discharge and giving the physician
reassurance for the patients’ well-being. The lack of
documentation regarding length of antibiotic therapy
has been heavily debated and studies suggest shorter
antibiotic courses are safe and effective for an increasing
number of diagnoses [29–33]. In our study, there was a
remarkable similarity in duration of antibiotic therapy
between the various groups of diagnoses, both in-
hospital and post-discharge. For all patients, the mean
number of days of antibiotic therapy were 10.6 days and
the range for the various groups were narrow (9.3 to
12.5 days) when post-discharge therapy was included.
There is a need for more studies, informing policy-
makers and clinicians about the optimal duration of
antibiotic therapy for individual diagnosis, both in-
hospital and for post-discharge use.
This study has some limitations. When assessing adher-
ence to guidelines on initiation of treatment, we used the
indication for treatment stated in the electronic medical
record, and this was usually a working diagnosis on admis-
sion. The diagnosis may change with more data and re-
sults available. To check whether this constituted a major
issue for interpretation of data, we looked at the coher-
ence between indication for treatment and the infection
discharge diagnosis (if present) in the discharge letter. The
group of diagnoses for which this might be an issue, is
sepsis, where accuracy between indication for treatment
and discharge diagnosis was low. During the study period,
SIRS-criteria were used to screen patients for sepsis. SIRS
identify more patients with suspected sepsis than the
qSOFA score, which is currently in use. The low accuracy
in this group could be due to lack of documentation of
sepsis at discharge, with only the original focus of the in-
fection often documented in discharge papers. It is pos-
sible that review of therapy took place without
modifications to the patient’s antibiotic regimen. Such re-
views were not identified during data collection and repre-
sents a limitation to this study. We also did not take
Table 5 Identified gaps and potential targets for antibiotic stewardship interventions
Gaps identified Potential targets
Guideline adherence increased the use of narrow spectrum WHO
Access group antibiotics in this study setting
Promoting adherence to guidelines when prescribing empirical antibiotic
therapy
Antibiotic therapy was initiated in the emergency room for 83.6% of
patients
Targeting antibiotic prescribing in the emergency room, focusing on first
line clinical staff
Non-adherence to antibiotic guideline was associated with admittance
from another institution
Understanding the drivers for non-adherence in patients admitted from
institutions and focusing on antibiotic prescribing for this group of
patients
Non-adherence to antibiotic guideline was associated with the place of
initiation of therapy, both regarding hospital site and wards compared
to emergency room
Understanding the cultural and contextual drivers for antibiotic
prescribing across institutions and specialties
Mean length of antibiotic therapy was similar across very different groups
of diagnosis.
Focusing on reducing the duration of antibiotic therapy safely, in
accordance with emerging evidence on duration of antibiotic treatment
Antibiotics prescribed upon discharge contributed significantly to the
total days of antibiotic therapy and the appropriateness of this practice
is often not clear
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dosing into consideration when assessing adherence to
guidelines and modification of therapy. Appropriateness
of antibiotic therapy was not evaluated after initial assess-
ment of adherence to guidelines for empirical antibiotic
treatment. It is therefore unknown whether escalation, de-
escalation, stop or change was the best option for each in-
dividual patient. From the study by Skodvin et al., with pa-
tients derived from the same intervention study cohort,
we do however know that only 18% of patients had applic-
able microbiology test results and for only half of these pa-
tients (9% of the total cohort), these findings were used to
guide therapy [19].
The Nordic countries and the Netherlands are cur-
rently in a favourable position regarding antimicrobial
resistance and are still able to utilize the most ecologic-
ally friendly antibiotics in empirical regimens. Exploring
different ways of aggregating and analysing data to
understand hospital antibiotic prescribing processes are
however important in all countries and institutions, aim-
ing to identify targets for stewardship interventions.
Future studies should include assessment of appropri-
ateness of therapy throughout the hospital stay to have a
more comprehensive review of prescribing quality at
every step of the process. Identifying and studying con-
tributions from other healthcare professionals, like
nurses and pharmacist and the team effort in antibiotic
stewardship would also be valuable. As patient involve-
ment and empowerment is increasing, the contribution
of patients in antibiotic stewardship in hospital settings
should also be investigated. Such studies could contrib-
ute to the identification of more targets for antibiotic
stewardship interventions.
Conclusions
Analysis of patient level antibiotic prescribing data and
the use of WHO AWaRe to categorise antibiotic regimens
throughout the hospital stay, identified relevant targets for
antibiotic stewardship interventions in our population of
hospital inpatients. Identified targets included 1) adher-
ence to guidelines 2) focus on prescribing physicians in
the emergency room 3) understanding prescribing for pa-
tients admitted from an institution 4) organisational cul-
ture and 5) duration of antibiotic therapy.
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